Form 4 holding
CEO, Director
Entrada Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 517,290
- Estimated value
- $3,807,254
- Report date
- 02 Sep 2026
- Price
- $7.36
- Ownership
- Direct
Dipal Doshi - CEO, Director at Entrada Therapeutics, Inc.
Issuer-level insider activity
- Role
- CEO, Director
- Issuer ticker
- TRDA on Nasdaq
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
No buys or sells have been reported by Dipal Doshi since 14 Oct 2025
Reported holdings for Dipal Doshi in Entrada Therapeutics, Inc.
Form 4 holding
CEO, Director
Entrada Therapeutics, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 208,000
- Estimated value
- Report date
- 01 Mar 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transaction history for Dipal Doshi in Entrada Therapeutics, Inc.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.